This report values the global esoteric testing market at US$28.0B in 2025, up from an estimated US$20.3B in 2021 (a historical CAGR of approximately 8.4%), and forecasts growth to US$45.5B by 2030 at a 10.2% CAGR over 2026-2030. Growth accelerated after the post-pandemic normalization of infectious-disease molecular volumes in 2022, as oncology genomic profiling, minimal residual disease (MRD) monitoring, blood-based neurology biomarkers and expanded genetic testing lifted both test complexity and value per requisition. North America is the largest region at approximately 44% of 2025 revenue, anchored by the United States (US$11.09B), while Asia Pacific is the fastest-growing region at approximately 12.2% CAGR, led by China and India.
By testing type, oncology testing is the largest category at 26% share, while genetic and genomic testing is the fastest-growing at approximately 13.5% CAGR. Chemiluminescence immunoassay (CLIA) remains the leading technology platform at 28% share, but next-generation sequencing (approximately 18.0% CAGR) and digital PCR (approximately 17.0% CAGR) are expanding fastest. Oncology is the leading application at 28% share, while genetic and rare diseases are the fastest-growing application at approximately 13.3% CAGR. Serum is the largest specimen type at 26% share, while plasma, driven by liquid biopsy and blood-based biomarkers, is the fastest-growing at approximately 15.0% CAGR. Independent reference laboratories are the largest end-user group at 43% share, and specialty laboratories are the fastest-growing at approximately 13.0% CAGR.
Demand is underpinned by the rising burden of cancer, chronic, autoimmune and rare diseases, the expansion of precision medicine and targeted therapies that require companion diagnostics, falling sequencing costs, broader use of LC-MS/MS and multiplex assays, and hospital outsourcing of complex tests to reference networks. Key trends include MRD and liquid biopsy, pharmacogenomics, FDA-cleared blood tests for Alzheimer’s disease, AI-assisted interpretation, laboratory automation and consolidation through hospital-outreach acquisitions. Principal challenges include high test and equipment costs, reimbursement and coverage variability, evolving laboratory-developed-test oversight and EU IVDR requirements, specialist workforce shortages, bioinformatics complexity and limited access in emerging markets.
The competitive landscape is moderately consolidated at the top and fragmented in specialty niches: national networks such as Labcorp, Quest Diagnostics, Eurofins Scientific and Sonic Healthcare compete alongside academic reference laboratories such as Mayo Clinic Laboratories and ARUP Laboratories, oncology specialists such as NeoGenomics, and integrated laboratory-diagnostics groups such as H.U. Group. Competition centers on test-menu breadth, scientific depth, turnaround time, payer access and health-system partnerships. The market enters 2026 on a structurally growing trajectory, with genomics, oncology, neurology and emerging-market laboratory modernization expected to sustain double-digit growth through 2030.
By testing type, oncology testing is the largest category at 26% share, while genetic and genomic testing is the fastest-growing at approximately 13.5% CAGR. Chemiluminescence immunoassay (CLIA) remains the leading technology platform at 28% share, but next-generation sequencing (approximately 18.0% CAGR) and digital PCR (approximately 17.0% CAGR) are expanding fastest. Oncology is the leading application at 28% share, while genetic and rare diseases are the fastest-growing application at approximately 13.3% CAGR. Serum is the largest specimen type at 26% share, while plasma, driven by liquid biopsy and blood-based biomarkers, is the fastest-growing at approximately 15.0% CAGR. Independent reference laboratories are the largest end-user group at 43% share, and specialty laboratories are the fastest-growing at approximately 13.0% CAGR.
Demand is underpinned by the rising burden of cancer, chronic, autoimmune and rare diseases, the expansion of precision medicine and targeted therapies that require companion diagnostics, falling sequencing costs, broader use of LC-MS/MS and multiplex assays, and hospital outsourcing of complex tests to reference networks. Key trends include MRD and liquid biopsy, pharmacogenomics, FDA-cleared blood tests for Alzheimer’s disease, AI-assisted interpretation, laboratory automation and consolidation through hospital-outreach acquisitions. Principal challenges include high test and equipment costs, reimbursement and coverage variability, evolving laboratory-developed-test oversight and EU IVDR requirements, specialist workforce shortages, bioinformatics complexity and limited access in emerging markets.
The competitive landscape is moderately consolidated at the top and fragmented in specialty niches: national networks such as Labcorp, Quest Diagnostics, Eurofins Scientific and Sonic Healthcare compete alongside academic reference laboratories such as Mayo Clinic Laboratories and ARUP Laboratories, oncology specialists such as NeoGenomics, and integrated laboratory-diagnostics groups such as H.U. Group. Competition centers on test-menu breadth, scientific depth, turnaround time, payer access and health-system partnerships. The market enters 2026 on a structurally growing trajectory, with genomics, oncology, neurology and emerging-market laboratory modernization expected to sustain double-digit growth through 2030.
Table of Contents
1. Introduction
2. Market Size and Growth
3. Market Segmentation
4. Regional and Country Analysis
5. Technology, Application and Diagnostic Insights
6. Competitive Landscape
7. Company Profiles
8. Strategic Insights and Outlook
List of Tables and Figures
Companies Mentioned
- Labcorp
- Quest Diagnostics
- Eurofins Scientific
- Sonic Healthcare
- Mayo Clinic Laboratories
- ARUP Laboratories
- NeoGenomics
- H.U. Group Holdings
